Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. ETF
  3. VCYT
VCYT logo

VCYT

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

VCYT News

Veracyte Reports Strong Q4 2025 Earnings with 19% Revenue Growth

Feb 26 2026seekingalpha

Veracyte Reports Q4 Earnings Exceeding Expectations

Feb 25 2026seekingalpha

Veracyte to Participate in Investor Conferences

Feb 19 2026Newsfilter

Veracyte to Release Q4 and Full-Year 2025 Financial Results

Feb 04 2026Businesswire

Veracyte Inc Shares Enter Oversold Territory

Feb 04 2026NASDAQ.COM

Elekta EKTAY's Evo CT-Linac Receives FDA Clearance, Enhancing Personalized Radiation Therapy

Jan 19 2026NASDAQ.COM

Abbott Laboratories (ABT) Forecasts Q4 2025 Revenue of $11.79 Billion, Up 7.5%

Jan 19 2026NASDAQ.COM

Veracyte Projects 10%-13% Revenue Growth for 2026

Jan 11 2026Businesswire

Veracyte Reports $517M Full-Year Revenue, Up 16%

Jan 11 2026Newsfilter

Oncolytics Biotech Achieves 33% Response Rate with Pelareorep in KRAS-Mutant Colorectal Cancer

Dec 31 2025Newsfilter

Oncolytics Biotech Reports 33% Response Rate in KRAS-Mutant Colorectal Cancer with Pelareorep

Dec 31 2025PRnewswire

Veracyte Raises 2025 Sales Guidance to $510 Million Amid Positive Market Trends

Dec 31 2025Yahoo Finance

Veracyte Projects 14.1% Sales Growth to $508.6M in 2025

Dec 30 2025NASDAQ.COM

Veracyte to Present at 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026

Dec 29 2025Businesswire

HOLX's Innovative AI Mammography Identifies Overlooked Breast Cancer Cases

Dec 17 2025NASDAQ.COM

Meihua International Medical Technologies, Fly-E Group, and Other Major Stocks Decline in Pre-Market Trading on Monday

Dec 08 2025Benzinga